GVK Biosciences: European Medicines Agency recommends suspending medicines over flawed studies
Medicines considered critically important for patients to remain available
A number of medicines for which authorisation in the European Union (EU) was primarily based on clinical studies conducted at GVK Biosciences in Hyderabad, India should be suspended, says the European Medicines Agency (EMA). The recommendation is based on findings from an inspection that raised concerns about how GVK conducted studies at the Hyderabad site on behalf of marketing authorisation holders.
Upon the request of the European Commission, EMA’s Committee for Medicinal Products for Human Use (CHMP) looked at over 1,000 pharmaceutical forms and strengths of medicines studied at the GVK site. For over 300 of them, sufficient supporting data from other sources were available; these will therefore remain on the market in the EU as EMA is satisfied with the available data.
For medicines that lack data from other studies, the CHMP recommended suspension unless they are of critical importance for patients because alternatives will not be able to meet patients’ needs. There is no evidence of harm or lack of effectiveness linked to the conduct of studies by GVK Biosciences.
The decision on whether a medicine is critical for patients lies with the national authorities of EU Member States depending on the situation in their country. For medicines that are considered critical, companies are given 12 months to submit additional data.
The European Medicines Agency (EMA) will relocate to Amsterdam in the Netherlands. This decision was taken today by the EU 27 Member States in the margins of the General Affairs Council (Art.50). The Agency now has just over 16 months to prepare for the move and take up its operations in Am ... more
The European Medicines Agency (EMA) has developed and initiated a business continuity plan to deal with the uncertainty and workload implications linked to the United Kingdom’s (UK’s) withdrawal from the European Union (EU) and the Agency’s relocation.
“Preparing for the move, managing the ... more
Merck and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of avelumab (BAVENCIO®) as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC), a rar ... more
GVK Biosciences announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University. As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the target validation, lead identi ... more
GVK Biosciences (GVK BIO) announced that it was awarded the Frost & Sullivan 2011 Best Practices Award for Growth Leadership in the Contract Research Services Market.
The Frost & Sullivan Award for Growth Leadership is presented to the company that has demonstrated excellence in capturing a ... more
GVK Biosciences Private Limited (GVK BIO) announced that it received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International for its animal facilities.
The accreditation demonstrates GVK BIO’s commitment to high standard ... more
GVK Biosciences, Asia’s leading Contract Research Organization, delivers integrated research services to big Pharma and Biotech companies globally. GVK BIO accelerates the Drug Discovery and Development process of its customers through science and innovation. GVK BIO has a diverse customer ... more